SEC Filing Summary: RXi Pharmaceuticals Corporation (8-K)
Business Context and Reporting Period
This Form 8-K was filed by RXi Pharmaceuticals Corporation (now known as SELLAS Life Sciences Group, Inc.) on January 22, 2009, reporting events occurring on January 15, 2009. The filing addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate events and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the expansion of the Board of Directors from five to six members. On January 15, 2009, the Board appointed Dr. Rudolph Nisi as a Class I director to fill the newly created vacancy. His term is set to expire at the 2011 annual meeting of stockholders. Dr. Nisi was not appointed to any Board committees at the time of his appointment, and the appointment was not made pursuant to any agreement with a third party.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, risk factors, contingencies, or unusual items. The document focuses solely on the director appointment and includes a press release issued on January 22, 2009, as an exhibit.
Key Facts for Investor Verification
- Dr. Rudolph Nisi was appointed to the Board of Directors on January 15, 2009.
- The Board size was increased to six members to accommodate this appointment.
- Dr. Nisi's director term expires at the 2011 annual meeting of stockholders.
- No financial data or operational metrics are disclosed in this specific filing.